Use a patient case to learn about managing adverse events with immunotherapy in patients with NSCLC.
This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.
The goal of this activity is to address how to start integrating immune checkpoint inhibitors into lung cancer treatment.
Approximate Time to Complete: 15 minutes
Course Available Beginning: Dec. 6, 2016
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Identify strategies to avert and manage treatment-related adverse events in patients with advanced non-small cell lung cancer (NSCLC)